Weight gain

Pfizer’s LORBRENA® CROWN Study Shows Majority of Patients with ALK-Positive Advanced Lung Cancer Living Beyond Five Years Without Disease Progression

Retrieved on: 
fredag, maj 31, 2024
Research, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, Traffic barrier, Lung, Principal, Progression-free survival, Patient, Diarrhea, Anaplastic lymphoma kinase, Headache, Cough, Weight gain, Learning, Hypercholesterolemia, Risk, Hypertriglyceridemia, Inc., Lung cancer, Doctor of Philosophy, Arthralgia, PFS, Disease, Edema, NSCLC, APLS, Death, Peripheral neuropathy, HR, Abstract, Periodic breathing, Hypertension, PFE, ASCO, Journal, Brain, Society, ALK, Confidence interval, Aes, MBBS, Crizotinib, Pharmaceutical industry

Further, 60% of patients treated with LORBRENA (95% CI, 51-68) were alive without disease progression after five years compared to 8% (3-14) on the XALKORI treatment arm.

Key Points: 
  • Further, 60% of patients treated with LORBRENA (95% CI, 51-68) were alive without disease progression after five years compared to 8% (3-14) on the XALKORI treatment arm.
  • “These results from the CROWN trial are unprecedented, as the majority of patients on LORBRENA are living beyond five years without disease progression,” said Roger Dansey, M.D., Chief Development Officer, Oncology, Pfizer.
  • “This updated analysis shows that LORBRENA helped patients live longer without disease progression, with the majority of patients experiencing sustained benefit for over five years, including nearly all patients having protection from progression of disease in the brain.
  • At the time of analysis, 50% of patients in the CROWN trial were still receiving LORBRENA compared to 5% of patients receiving XALKORI.

Altamira Therapeutics Provides Business Update

Retrieved on: 
tisdag, maj 28, 2024
Francs, Transport, AVS, Histamine, Patient, Weight gain, COVID-19, Amnesia, Swiss franc, Betahistine, Liver, Clinical trial, Messenger, Therapy, Dementia, Tourette syndrome, Orphan drug, Freezing, Research, Narcolepsy, RNA, Communication, Special, Prader–Willi syndrome, ADHD

HAMILTON, BERMUDA / May 28, 2024 / Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today provided a business update related to its RNA delivery platform, partnering of its legacy assets, corporate structuring and financial reporting.

Key Points: 
  • HAMILTON, BERMUDA / May 28, 2024 / Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today provided a business update related to its RNA delivery platform, partnering of its legacy assets, corporate structuring and financial reporting.
  • Further, the Company is about to merge two of its subsidiaries in Basel (Switzerland), Auris Medical AG and Altamira Therapeutics AG.
  • Following completion of the merger, the Altamira Group will comprise the parent company Altamira Therapeutics Ltd. (Hamilton, Bermuda), and its subsidiaries Altamira Therapeutics AG (Basel, Switzerland), Altamira Therapeutics Inc. (Newark DE, USA), Otolanum AG (Basel, Switzerland) as well as the associated company Altamira Medica AG (Basel, Switzerland).
  • Altamira plans to release its half-year 2024 financial results and business update report by the end of August 2024.

Xenon Pharmaceuticals Presents Data from Phase 2 X-NOVA Clinical Trial of Azetukalner in Major Depressive Disorder at the American Society of Clinical Psychopharmacology 2024 Annual Meeting

Retrieved on: 
tisdag, maj 28, 2024
Xenon, Patient, Novel, Weight gain, BAI, MDD, Major depressive disorder, Depression, Anxiety, Political moderate, Incidence, DSM-IV codes, ASCP, Society, Physician, Clinical Global Impression, Anhedonia, Annual general meeting, Surveying

VANCOUVER, British Columbia, May 28, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, announced data presentations highlighting azetukalner (XEN1101) clinical data in major depressive disorder (MDD) at the American Society of Clinical Psychopharmacology (ASCP) 2024 Annual Meeting in Miami, FL.

Key Points: 
  • VANCOUVER, British Columbia, May 28, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, announced data presentations highlighting azetukalner (XEN1101) clinical data in major depressive disorder (MDD) at the American Society of Clinical Psychopharmacology (ASCP) 2024 Annual Meeting in Miami, FL.
  • Mr. Ian Mortimer, Xenon’s President and Chief Executive Officer, stated, “We are pleased to present these data from our Phase 2 proof-of-concept X-NOVA study of azetukalner in MDD at the ASCP meeting.
  • The primary endpoint of the study was a change in the Montgomery-Åsberg Depression Rating Scale, or MADRS, at week 6.
  • There were no statistically significant differences in change from baseline BAI total scores to week 6 between placebo and azetukalner groups.

Noema Pharma Announces First Patient Dosed in Phase 2a Study of NOE-115, a First-In-Class Investigational Therapy for the Treatment of Vasomotor Symptoms and Additional Symptoms Associated with Menopause

Retrieved on: 
onsdag, maj 22, 2024
Patient, Weight gain, Neuroscience, Safety, Health, MD, VMS, Hot, Woman, Fatigue, Menopause, Quality of life

These include vasomotor symptoms as well as weight gain, significant daytime fatigue and cognitive difficulties.”

Key Points: 
  • These include vasomotor symptoms as well as weight gain, significant daytime fatigue and cognitive difficulties.”
    NOE-PPM-201 is a Phase 2a open-label study that is designed to examine the safety and efficacy of NOE-115, a monoamine modulator, in patients with vasomotor symptoms due to menopause and assess additional associated non-VMS menopausal symptoms.
  • The trial will initially evaluate 30 women with moderate to severe VMS at 6 centers in the US.
  • She added, “there remains a significant need for innovative treatments that address the broader group of symptoms that women in the menopause transition struggle with.
  • NOE-115 may be a unique therapeutic option with the potential to target multiple moderate-to-severe CNS-mediated menopausal symptoms.”

New Study Published in JCO Precision Oncology Shows Myriad Genetics' Prolaris Test Can Predict Benefit of Hormone Therapy Treatment in Men with Localized Prostate Cancer

Retrieved on: 
torsdag, maj 16, 2024
Patient, Cohort (statistics), Doctor of Philosophy, University, Weight gain, Genetic testing, Myriad Genetics, Risk, JCO, MYGN, Male, Huntsman Cancer Institute, Conference, CCR, MD, ADT, Death, Prostate cancer, Genetics, ASCO, Medicine, Poster, Society, RT, Metastasis

SALT LAKE CITY, May 16, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced that JCO Precision Oncology has published a study showing a clinical cell-cycle risk (CCR) score can accurately predict the benefit of adding androgen deprivation therapy (ADT) to radiation therapy (RT) in men with localized prostate cancer.

Key Points: 
  • (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced that JCO Precision Oncology has published a study showing a clinical cell-cycle risk (CCR) score can accurately predict the benefit of adding androgen deprivation therapy (ADT) to radiation therapy (RT) in men with localized prostate cancer.
  • Guidelines currently recommend adding ADT to RT in certain patients with localized prostate cancer.
  • However, patients with a Prolaris CCR score above the multimodal threshold can reduce risk of metastasis by 8.19% on average by adding ADT to RT.
  • In consultation with their providers, many of these men may elect to forgo ADT based on the information in their Prolaris reports.”

World Anti-obesity Drugs Market Report 2024-2034: Top Anti-obesity Products, Pipeline Analysis by Phase, New Product Launches - ResearchAndMarkets.com

Retrieved on: 
tisdag, maj 21, 2024
Vitamins, Supplements, Pharmaceutical, Fitness & Nutrition, Health, Type 2 diabetes, Diabetes, Patient, Weight gain, Organization, DSM-IV codes, Obesity, Conditional sentence, Research, Global health, Cancer, Policy, Urbanization, Innovation, Quality of life, Pharmaceutical industry

The "Anti-obesity Drugs Market Report 2024-2034" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Anti-obesity Drugs Market Report 2024-2034" report has been added to ResearchAndMarkets.com's offering.
  • Overall world revenue for Anti-obesity Drugs Market, 2024 to 2034 in terms of value the market, will surpass US$ 78.00 billion in 2034, the work calculates.
  • The Anti-obesity Drugs Market Report 2024-2034: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics.
  • Key players within the Anti-obesity drugs market compete based on the diversity and efficacy of their product portfolios.

Hims & Hers Announces Access to GLP-1 Injections, Passing Cost Savings Onto Customers

Retrieved on: 
måndag, maj 20, 2024
Pharmaceutical, Fitness & Nutrition, Health, Telemedicine, Virtual Medicine, Partnership, Diabetes, Cardiovascular disease, Weight gain, Sleep, Food, Obesity, Overweight, Exercise, FDA, Pharmacy, Hers, Injection, Weight loss, Human, Multimedia, Medicine, Pharmaceutical industry

(Photo: Business Wire)

Key Points: 
  • (Photo: Business Wire)
    The company now offers access to GLP-1 injections in addition to weight management oral medication kits, so that customers can truly personalize their weight loss experience.
  • Providing access to compounded GLP-1s means eligible customers can use medications with the same active ingredient as Ozempic® and Wegovy® without navigating the shortages and costs that are currently limiting access to the branded medications.
  • “We’ve leveraged our size and scale to secure access to one of the highest-quality supplies of compounded GLP-1 injections available today.
  • Building on that success, offering access to compounded GLP-1s gives medical providers and customers consistent and affordable access to effective, trusted and safe medications.

Newron Reports Compelling Additional Data Documenting the Efficacy of Evenamide in Pivotal Study 008A in Poorly Responding Schizophrenia Patients

Retrieved on: 
måndag, maj 13, 2024
Mental Health, Research, FDA, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Science, Patient, Weight gain, Positive, Psychosis, PANSS, Metabolic syndrome, Medication, Safety, Clozapine, Evenamide, MD, EPS, CNS, Observation, Clinical Global Impression, Schizophrenia, XETRA, Peripheral nervous system, Blood, ANCOVA, Pharmaceutical industry

Study 008A is the first well-designed study demonstrating efficacy of an adjunctive treatment in benefiting patients who do not respond to their current antipsychotic.

Key Points: 
  • Study 008A is the first well-designed study demonstrating efficacy of an adjunctive treatment in benefiting patients who do not respond to their current antipsychotic.
  • Evenamide also is the first glutamate modulator to demonstrate efficacy in inadequately responding patients with schizophrenia in a placebo-controlled study.
  • Ravi Anand, MD, Chief Medical Officer of Newron, stated: “These new efficacy results from study 008A attest to the clinical relevance of the benefits for patients, based on the primary and key secondary endpoints.
  • Most importantly, the benefits noted on the efficacy measures increased up to Day 29, thus suggesting larger and enduring effects during longer term treatment.

Geisinger enrolls first patient in amyloid cardiomyopathy trial

Retrieved on: 
fredag, maj 10, 2024
Blood pressure, Patient, B cell, Parent, Amyloidosis, Weight gain, Cardiac amyloidosis, Protein, Heart, Heart failure, Clinical trial, Diagnosis, Travel, Safety, Swelling, Weakness, MD, Blood, Hypoesthesia, Research, Amyloid cardiomyopathy, ATTR, Extremities, Genotype, Quality of life, Carpal tunnel syndrome, TTR

DANVILLE, Pa., May 10, 2024 /PRNewswire/ -- Cardiologist Brendan Carry, MD, and a team of Geisinger physicians have enrolled the first patient in the U.S. into a cardiac amyloidosis trial.

Key Points: 
  • DANVILLE, Pa., May 10, 2024 /PRNewswire/ -- Cardiologist Brendan Carry, MD, and a team of Geisinger physicians have enrolled the first patient in the U.S. into a cardiac amyloidosis trial.
  • "If a patient qualifies for the clinical trial, it will allow us to provide a treatment option when they receive an amyloidosis diagnosis without having to travel outside of the region for care," said Dr.
  • "Geisinger is at the forefront of research and technological advancements that allow for better patient outcomes and improvements in their quality of life."
  • The trial is a phase 3, randomized, double-blind, placebo-controlled study that evaluates the safety and effectiveness of amyloid deplete ALXN2220 in participants with transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM).

Clearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD Treatment

Retrieved on: 
tisdag, maj 7, 2024
Hebrew University of Jerusalem, Selective serotonin reuptake inhibitor, Weight gain, Hope, Post-traumatic stress disorder, Nausea, PTSD, Al-Quds, Insomnia, Serotonin–norepinephrine reuptake inhibitor, Therapy, Intellectual property, Anxiety, Pharmaceutical industry

This agreement provides Clearmind with exclusive global rights to further develop, manufacture, and commercialize innovative compounds invented by Professors Rami Yaka, Ahmed Masaewa and Avi Priel from the Hebrew University.

Key Points: 
  • This agreement provides Clearmind with exclusive global rights to further develop, manufacture, and commercialize innovative compounds invented by Professors Rami Yaka, Ahmed Masaewa and Avi Priel from the Hebrew University.
  • These novel compounds are targeted at treating post-traumatic stress disorder (PTSD) and other mental health conditions.
  • The global market for PTSD treatment, valued at $16.8 billion in 2023, is expected to reach $27.37 billion by 2033, according to Future Market Insights.
  • Under the terms of the agreement, Clearmind receives exclusive rights to develop, manufacture, and commercialize novel compounds for treating PTSD and other mental health disorders.